Unknown PHASE3 INTERVENTIONAL 2-arm NCT02244658

Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia

Recombinant Human Thrombopoietin (rhTPO) in Management of Chemotherapy-induced Thrombocytopenia in Acute Myelocytic Leukemia: a Multicenter Clinical Trial

Sponsor: Shandong University

Conditions Acute Myelocytic Leukemia Antineoplastic Adverse Reaction Thrombocytopenia

Interventions rhTPO

Updated 6 times since 2017 Last updated: Apr 18, 2016 Started: Sep 30, 2014 Primary completion: Jun 30, 2017 Completion: Aug 31, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Acute Myelocytic Leukemia and Antineoplastic Adverse Reaction, this trial is ongoing. The trial is conducted by Shandong University and has accumulated 6 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3
Apr 2018 — Jun 2018 [monthly]

Unknown Status PHASE3

Status: Recruiting → Unknown Status

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Recruiting PHASE3

First recorded

Sep 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shandong University

Data source: Shandong University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Jinan, China